ETXP.F Stock Overview
Engages in drug discovery research activities in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
e-therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.13 |
| 52 Week High | US$0.22 |
| 52 Week Low | US$0.13 |
| Beta | 0.48 |
| 11 Month Change | 0% |
| 3 Month Change | -7.14% |
| 1 Year Change | -55.17% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| ETXP.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.7% | 0.3% |
| 1Y | -55.2% | 15.2% | 31.1% |
Return vs Industry: ETXP.F underperformed the US Biotechs industry which returned 13.7% over the past year.
Return vs Market: ETXP.F underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| ETXP.F volatility | |
|---|---|
| ETXP.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ETXP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ETXP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 35 | Ahmad Mortazavi | www.etherapeutics.co.uk |
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and increases automation; and GalOmic, RNA interference (RNAi) platform that generates potent and safe GalNAc-siRNA therapeutics to selectively silence novel disease-associated genes in hepatocytes. Its preclinical products are ETX-312 to treat metabolic dysfunction-associated steatohepatitis; and ETX-407 for the treatment of dry age-related macular degeneration.
e-therapeutics plc Fundamentals Summary
| ETXP.F fundamental statistics | |
|---|---|
| Market cap | US$75.96m |
| Earnings (TTM) | -US$14.50m |
| Revenue (TTM) | US$412.94k |
184.0x
P/S Ratio-5.2x
P/E RatioIs ETXP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETXP.F income statement (TTM) | |
|---|---|
| Revenue | UK£318.00k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£318.00k |
| Other Expenses | UK£11.48m |
| Earnings | -UK£11.17m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.019 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,511.32% |
| Debt/Equity Ratio | 0% |
How did ETXP.F perform over the long term?
See historical performance and comparison